ScholarX: AHN, MYUNG JU

Detailed Information

AHN, MYUNG JU (안명주)

Medicine (Medicine)

Research Area

Tel 02-3410-3438
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

NSCLC:63||Nonsmall cell lung cancer:48||nonsmall cell lung cancer:43||Immunotherapy:22||EGFR:18||Epidermal growth factor receptor:18||EGFR mutation:17||osimertinib:17||Lung cancer:16||T790M:14||Osimertinib:12||PDL1:12||Nonsmallcell lung cancer:12||immunotherapy:12||Lazertinib:11||Chemotherapy:10||nonsmallcell lung cancer:10||pembrolizumab:10||immune checkpoint inhibitor:10||Cisplatin:10||Non–small cell lung cancer:10||ROS1:9||Immune checkpoint inhibitor:9||ALK:9||Nonsmallcell lung carcinoma:9||Carcinoma:9||Tyrosine kinase inhibitor:9||Gefitinib:9||EGFRTKI:8||Anaplastic lymphoma kinase:8||brigatinib:8||Clinical trial:8||Pemetrexed:8||Cancer:8||overall survival:8||Targeted therapy:8||crizotinib:8||prognosis:8||lung cancer:8||Durvalumab:8||Adenocarcinoma:7||Biomarkers:7||gefitinib:7||tyrosine kinase inhibitor:7||Pembrolizumab:7||Nonsmall cell lung cancer (NSCLC):7||Small cell lung cancer:7||KRAS:7||Immunohistochemistry:7||Brigatinib:6||concurrent chemoradiotherapy:6||Nonsmall cell lung carcinoma:6||Erlotinib:6||Brain metastasis:6||nonsmall cell lung cancer:6||nextgeneration sequencing:6||Tyrosine kinase inhibitors:6||Prognosis:6||AZD9291:6||Crizotinib:6||Biomarker:5||pemetrexed:5||Epidermal growth factor receptor (EGFR):5||Mutation:5||Quality of life:5||Overall survival:5||TKI:5||Concurrent chemoradiotherapy:5||brain metastases:5||small cell lung cancer:5||Recurrence:5||Survival:5||nonsmall cell lung cancer (NSCLC):5||cisplatin:4||ctDNA:4||Chemoradiotherapy:4||Response criteria:4||CNS metastases:4||Afatinib:4||adenocarcinoma:4||F18FDG PET/CT:4||Acquired resistance:4||Stroke:4||Adjuvant chemotherapy:4||PDL1 expression:4||Immune checkpoint inhibitors:4||Hyperprogressive disease:4||plasma:4||NonSmall Cell Lung Cancer:4||Asian:4||leptomeningeal metastases:4||EGFR TKI:4||lung adenocarcinoma:4||Lung:4||ros1:4||Head and neck cancer:4||entrectinib:4||Entrectinib:4||biomarkers:4||Tumor mutation burden:3||Leptomeningeal metastases:3||Tumor response assessment:3||Metastasis:3||antiPD1:3||Thymoma:3||PIK3CA:3||Staging:3||combination:3||SCLC:3||machine learning:3||computational biology:3||afatinib:3||Ceritinib:3||lung:3||N2 disease:3||nonsmallcell lung:3||Thymic epithelial tumor:3||Korea:3||adjuvant chemotherapy:3||N2:3||Lung adenocarcinoma:3||Tyrosine kinase inhibitor (TKI):3||Patientreported outcomes:3||Adjuvant:3||T cell:3||bevacizumab:3||Neoadjuvant chemoradiotherapy:3||Head and neck neoplasms:3||biomarker:3||Docetaxel:3||Stage IIIA:3||Efficacy:3||Toxicity:3||Outcomes:3||Brain metastases:3||Neoplasms:3||Radiation therapy:3||Dacomitinib:3||cancer:3||nasopharyngeal cancer:3||radiomics:3||Receptor:3||durvalumab:3||ErbB receptors:3||Surgery:3||Next generation sequencing:3||survival:3||Nintedanib:3||MEK inhibitor:3||Coagulopathy:3||Progressionfree survival:3||epidermal growth factor receptor:3||tepotinib:3||CNS:3||chemoradiotherapy:3||vibostolimab:2||volumetry:2||Advanced nonsmall cell lung cancer:2||<sup>18</sup>FFDG PET/CT:2||efficacy:2||Dynamics:2||Firstline therapy:2||epidermal growth factor:2||epidermal growth factor receptor (EGFR):2||South Korea:2||epidermal growth factor receptor mutation:2||Leptomeningeal metastasis:2||Squamous cell:2||Squamous cell carcinoma of head and neck:2||Squamous cell carcinoma of the head and neck:2||PD1:2||Stage III NSCLC:2||Clinical trials:2||fibroblast growth factor receptor:2||Liquid biopsy:2||G2032R:2||Subtype:2||Cohort:2||Alectinib:2||head and neck cancer:2||head and neck cancers:2||PET/CT:2||head and neck squamous cell carcinoma:2||head and neck squamous cell carcinoma (HNSCC):2||Lung neoplasms:2||human:2||Lymph node:2||hyperprogression:2||hypopharyngeal cancer:2||Gemcitabine:2||ifosfamide:2||Palbociclib:2||Palliative chemotherapy:2||TIGIT:2||Bintrafusp alfa:2||immune checkpoint inhibitors:2||M7824:2||MET:2||immunohistochemistry:2||immunology:2||MET amplification:2||Tepotinib:2||EGFR mutations:2||laryngeal cancer:2||MET exon 14 skipping mutation:2||lazertinib:2||leptomeningeal disease:2||Thrombosis:2||Guideline:2||liquid biopsy:2||Thymic carcinoma:2||HER2:2||Phase II:2||maintenance therapy:2||Thymus:2||EGFRmutated NSCLC:2||MRI:2||metabolic tumor volume:2||Total lesion glycolysis:2||ALK tyrosine kinase inhibitor:2||Maintenance therapy:2||EGFRm:2||Head and neck squamous cell carcinoma:2||Trimodality therapy:2||ERBB2:2||Postoperative complication:2||neoadjuvant concurrent chemoradiotherapy:2||Pralsetinib:2||Precision medicine:2||Predictive factor:2||ERCC1:2||Predictor:2||nimotuzumab:2||East Asian patients:2||objective response rate:2||Prognostic factors:2||Programmed cell death 1 receptor:2||Molecular subtype:2||EpCAM:2||paclitaxel:2||Automatically updated:2||Adenoid cystic carcinoma:2||patientreported outcomes:2||Mortality:2||pazopanib:2||peripheral blood:2||Epidermal growth factor:2||phase III:2||Pulmonary pleomorphic carcinoma:2||Immunecheckpoint inhibitor:2||precision medicine:2||adenoid cystic carcinoma:2||predictor:2||adjuvant therapy:2||ALKpositive NSCLC:2||prognostic factor:2||Immunerelated adverse event:2||prognostic value:2||RET:2||RET fusion:2||anaplastic lymphoma kinase:2||progressionfree survival:2||RET rearrangement:2||NTRK:2||Nasopharyngeal cancer:2||anticoagulants:2||ROS1 fusions:2||DNA sequencing:2||recurrence dynamics:2||Radiosurgery:2||Radiotherapy:2||resistance:2||Esophageal cancer:2||bintrafusp alfa:2||safety:2||salvage chemotherapy:2||biopsy:2||Neoadjuvant concurrent chemoradiotherapy:2||Esophageal neoplasms:2||CD39:2||smallcell lung cancer:2||AURA3:2||squamous cell carcinoma:2||squamous cell lung cancer:2||squamous esophageal cancer:2||surgery:2||Nextgeneration sequencing:2||Resistance:2||systems biology:2||targeted therapy:2||Ischemic stroke:2||chemotherapy:2||thromboembolism:2||circulating tumor DNA (ctDNA):2||circulating tumour DNA:2||circulatingtumor DNA:2||clinical trials:2||concurrent chemoradiation:2||Salivary duct carcinoma:2||Nonsmallcell lung:2||treatment:2||tremelimumab:2||tumor microenvironment:2||Nonsquamous nonsmall cell lung cancer:2||tyrosine kinase inhibitors:2||Circulating tumor DNA:2||Non–smallcell lung cancer:2||Anticoagulation:2||uncommon EGFR mutation:2||dovitinib:2||vandetanib:2||Drug therapy:2||AZD1775:2||Neoadjuvant:1||Neoadjuvant chemoradiation:1||Neoadjuvant concurrent:1||Neoplasm metastasis:1||Neoplasm staging:1||Neurokinin1 receptor antagonists:1||Never smoker:1||Neversmoker:1||Neversmokers:1||Nivolumab:1||NonSmallCell Lung:1||Nonadenocarcinoma:1||Nonsmall cell lung:1||Nonsmall cell lung Cancer:1||Nonsmall cell lung cancer with N2 disease:1||Nonsmallcell lung can:1||Nonsquamous nonsmall cell lung carcinoma:1||Non–small cell lung carcinoma:1||Non–smallcell lung cancer (NSCLC):1||Non–smallcell lung carcinoma:1||Oesophageal cancer:1||Oesophageal carcinoma:1||Oesophageal fistula:1||Oesophageal squamous cell carcinoma:1||Olaparib:1||Oligorecurrence:1||Oncogenic drivers:1||Oral cancer:1||Oropharyngeal neoplasms:1||Oxaliplatin:1||PARP inhibition:1||PCRfree RNA detection:1||PD1 blockade:1||PD1 inhibitor:1||PD1 inhibitors:1||PD1PDL1 blockade:1||PD1/PDL1:1||PDL1 inhibitors:1||PDL2:1||PET:1||PF06463922:1||PFS:1||PHAROS:1||PI3K alpha inhibitor:1||POU2F3:1||Paclitaxel:1||Papillary thyroid carcinoma:1||Passive smoking:1||Pathology:1||Patient care:1||Patient selection:1||Pemetrex:1||Perfusion magnetic resonance imaging (MRI):1||Peripheral blood:1||Peripheral blood human mononuclear cells:1||Persistent N2:1||Pharmacokinetics:1||Phase 1 study:1||Phase 2:1||Phase 3:1||Phase I:1||Phase III:1||Phospholipase D:1||Plasma cellfree DNA:1||Platinum:1||Platinum compound:1||Platinum doublet:1||Platinum refractory:1||Platinumbased combination chemotherapy:1||Pleomorphic carcinoma:1||Pleura:1||Polymorphism:1||Positron emission tomography:1||Positron emission tomography (PET):1||Positron emission–computed tomography:1||Postresistance management:1||Predictivity:1||Predictors:1||Preoperative chemothe:1||Presepsin:1||Prevalence:1||Prognostic:1||Prognostic factor:1||Programmed Cell Death 1:1||Programmed Cell Death 1 Receptor:1||Programmed cell death1 receptor:1||Programmed cell deathligand 1:1||Programmed death ligand 1:1||Programmed deathligand 1:1||Prophylactic cranial irradiation:1||Prospective study:1||Proton beam therapy:1||Proton therapy:1||Pulmonary adenocarcinoma:1||Pulmonary complication:1||Pulmonary embolism:1||Pulmonary toxicity:1||Pulmonary/Critical Care:1||Pulmonary/Critical Care General:1||Pulsatile dosing:1||QTcF:1||Quinazolines:1||RANOLM:1||RECIST:1||RECIST 1.1:1||RET alteration:1||RET tyrosine kinase inhibitor:1||RETrearranged NSCLC:1||RETrearrangement:1||ROS1 gene fusion:1||ROS1rearranged NSCLC:1||Radiation:1||Radiomics:1||Rare or complex mutations:1||Real world evidence:1||Real world database:1||Realtime updated system:1||Realworld:1||Realworld data:1||Realworld date:1||Realworld evidence:1||Recurrent:1||Recurrent and:1||Refractory:1||Repeat biopsy:1||Repeat tests:1||Resectability:1||Resistance mechanism:1||Respo:1||Response:1||Reverse transcriptionpolymerase chain reaction:1||SAIT301:1||SARSCoV2:1||SNPs:1||SUVmax:1||Safety:1||Salivary gland neoplasms:1||Salvage concurrent chemoradiation therapy:1||Savolitinib:1||Screening:1||Second primary cancer:1||Secondline:1||Sepsis:1||Septic shock:1||Single nucleotide polymorphism:1||Singlecell RNA sequencing:1||Size:1||Skeletalrelated event:1||Small biopsy:1||Small cell lung cancer (SCLC):1||Small cell lung carcinoma:1||Small molecules:1||Smallcell lung cancer:1||Smoking cessation:1||Smoking status:1||Somatic copy number alteration:1||Sorafenib:1||Sotorasib:1||Spinal cord compression:1||Sponsorinitiated clinical trial:1||Squamous carcinoma:1||Squamous cell lung cancer:1||Stage III:1||Stage IIIAN2:1||Stereotactic radiosurgery:1||Stereotactic radiosurgery (SRS):1||Structured query language:1||Subsolid nodule:1||Sum of target lesions:1||Supraclavicular lymph node:1||Surveillance:1||Survival analysis:1||Symptoms:1||Systemic chemotherapy:1||T cell senescence:1||T cells:1||TLymphocytes:1||T4b oesophageal cancer:1||T790M mutation:1||T790 M mutation:1||TCF1:1||TGFbeta:1||TGFβ:1||TP53:1||TPX0005:1||Taiwan:1||Tanibirumab:1||Target:1||Target therapy:1||Targeted exome sequencing:1||Targeted nextgeneration sequencing:1||Targeted sequencing:1||Targeted therapies:1||Tarlatamab:1||Therapy:1||Thirdgeneration EGFR tyrosine kinase inhibitor:1||Thirdgeneration EGFRTKI:1||Thymic Epithelial Tumors:1||Thymic epithelial tumor (TET):1||Thymic epithelial tumors:1||Thymic tumor:1||Thymidylate synthase:1||Thyroid:1||Thyroid neoplasms:1||Time to next treatment:1||Tolllike receptor agonist:1||Trametinib:1||Transient asymptomatic pulmonary opacities:1||Translation to patients:1||Treatment:1||Treatment postcrizotinib:1||Treatments in Oncology:1||Treg cells:1||Tremelimumab:1||Tretinoin:1||Tuberculosis:1||Tumor Associated Macrophage:1||Tumor Biomarkers:1||Tumor angiogenesis:1||Tumor biomarker:1||Tumor burden:1||Tumor lysis syndrome:1||Tumor microenvironment:1||Tumour mutation burden:1||Twost:1||Tyrosine:1||Tyrosinekinase inhibitor:1||UICC 7th TNM stage:1||Umbrella trial:1||Uncommon EGFR:1||Uncommon mutation:1||Unresectable:1||Unresectable locally advanced non–small cell lung cancer:1||Unsuspected N2 lymph node:1||VEGFR2 inhibitor:1||Validation:1||Value of therapy:1||Vandetanib:1||Vascular endothelial growth factor receptors:1||Vortex keratopathy:1||WHO histologic classification:1||Wee1:1||Weekly docetaxel:1||White ethnicity:1||Whole brain radiation therapy (WBRT):1||Xray computed tomography:1||YAP1:1||[18F]FDGPET/CT:1||acquired resistance:1||actionable genetic alterations:1||acute:1||adavosertib:1||adjuvant:1||adjvuant therapy:1||advanced NSCLC:1||advanced solid tumors:1||afainib:1||alectinib:1||amivantamab:1||amphiregulin:1||anaplastic lymphoma kinaserearranged (ALK+) NSCLC:1||antiPD1/PDL1:1||antitumor effects:1||antibody application:1||antibody catenation:1||arsenical:1||artificial intelligenceanalysis:1||atezolizumab:1||autoimmune disease:1||autoimmune disorders:1||avelumab plus axitinib:1||avidity enhancement:1||axitinib:1||barecetamab:1||binimetinib:1||bloodbrain barrier penetration:1||brain:1||cMET:1||ckit:1||cmet:1||cMET:1||cancer biology:1||cancer diagnosis:1||cancer recurrence:1||carcinoma:1||cardiac:1||casefatality rate:1||cell adhesion molecules:1||cellfree DNA:1||central nervous system:1||central nervous system metastases:1||cerebral stroke:1||ceritinib:1||cetuximab:1||chemokine (CXC motif) ligand 13:1||circulating tumor DNA:1||clinical trial:1||combined modality therapy:1||comprehensive genomic profiling:1||conjugate:1||consensus:1||consensus guideline:1||consolidation therapy:1||dacomitinib:1||de novo:1||decision curve analysis:1||deep neural network:1||diagnostic value:1||discontinuation:1||distant metastases:1||distant metastasis:1||docetaxel:1||docetaxelPM:1||driver mutation:1||droplet digital PCR:1||duration of treatment:1||early stage:1||edoxaban:1||elderly:1||emphysema:1||encorafenib:1||encorafenib plus binimetinib:1||enoxaparin:1||epidermal growth factor receptor (EGFR) mutation:1||epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI):1||epidermal growth factor receptor mutant nonsmallcell lung cancer:1||epidermal growth factor receptortyrosine kinase inhibitor:1||epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs):1||erlotinib:1||esophageal cancer:1||esophageal squamous cell:1||ethnic difference:1||exon 19Del:1||exon 20:1||expert panel:1||extensive:1||extracellular traps:1||extracellular vesicles:1||fibroblast growth factor receptor 1 (FGFR1) amplification:1||ficlatuzumab:1||flow cytometry:1||fluorescence:1||followup:1||fragmentome:1||gene expression profile:1||gene fusion:1||gene mutations:1||genetic alteration:1||genomewide association study:1||glycerophospholipids:1||head and neck:1||head and neck squamous cell cancer:1||hematologic:1||hepatitis B virus:1||hepatitis B virus reactivation:1||histologic type:1||histological grade:1||homologydependent recombination deficiency:1||human leukocyte antigen:1||hypercoagulability:1||hypopharynx cancer:1||imatinib:1||immune check point inhibitor:1||immune check point inhibitors:1||immune checkpoint inhibition:1||immune checkpoint inhibitor (ICI):1||immune checkpoint therapy:1||immune profiling:1||immune related response:1||immunecheckpoint inhibitor:1||induction chemotherapy:1||interaction:1||interstitial lung disease:1||intracranial radiotherapy:1||intrathecal therapy:1||intratumoral heterogeneity:1||irAE:1||irinotecan:1||ischemic:1||kras:1||latestage biopsy:1||leptomeningeal metastasis:1||limited disease (LD):1||locally advanced stage III:1||locoregional r:1||logistic regression:1||longterm survival:1||longterm tolerability:1||maintenance:1||matrix metalloproteinase:1||mechanisms of resistance:1||mediastinoscopy:1||mediastinum:1||medullary thyroid cancer:1||metastatic NSCLC:1||metastatic nonsmall cell lung cancer:1||methotrexate:1||microscopic N2:1||minimal residual disease:1||mitomycin C:1||molecular biophysics:1||molecular markers:1||molecular subtype:1||monotherapy:1||multiplex IHC:1||myeloidderived suppressor cell:1||nanobarcoding:1||nanomechanical detection:1||nasopharyngeal carcinoma:1||neoadjuvant CCRT:1||neoplasm drug resistance:1||neoplasm metastasis:1||neoplasm staging:1||neuroendocrine tumors:1||neutrophiltolymphocyte ratio:1||neversmoker:1||neversmokers:1||new technology:1||nintedanib:1||nonsmallcell lun:1||nonsmallcell lung cancer:1||nonsquamous:1||nonsquamous nonsmall cell lung cancer:1||non–small cell lung:1||non–small cell lung cancer:1||nuclear protein in testis:1||nucleosomes:1||omics:1||or metastatic:1||oropharynx cancer:1||osimertinib (AZD9291):1||outcome:1||outcomes:1||p53:1||pathologic complete response:1||pathway analysis:1||patientderived xenograft:1||pattern of recurrence:1||pharmacogenetics:1||pharyngeal cancer:1||phase I:1||phase III study:1||phosphorylated signal transducer and activator of transcription 3:1||plain language summary:1||platelettolymphocyte ratio:1||polygenic risk score:1||pooled analysis:1||poorly differentiated carcinoma:1||positron emission tomography (PET):1||postPD:1||predictive biomarker:1||predictive biomarkers:1||predictive factor:1||prevalence:1||primary resistance:1||prognostic biomarker:1||prognostic model:1||programmed cell death ligand1:1||programmed cell death protein 1:1||programmed cell death1:1||programmed death ligand 1 (PDL1):1||programmed death1 (PD1):1||programmed deathligand 1:1||promyelocytic:1||protein kinase inhibitors:1||proteolysis:1||pseudotime analysis:1||pulmonary lymphangitic carcinomatosis:1||quality of life:1||quavonlimab:1||radiation:1||radiation pneumonitis:1||radiation therapy:1||radiotherapy:1||random forest:1||rebiopsy:1||recurrence pattern:1||recurrent disease:1||response rate:1||response signature:1||risk stratification:1||s staging system:1||salivary duct carcinoma:1||salivary gland cancer:1||salvage regimen:1||sample size calculation:1||single nucleotide polymorphism:1||singlecell RNA sequencing:1||small cell lung cancer (SCLC):1||small cell lung carcinoma:1||small noncoding RNAs:1||solid tumor:1||solid tumors:1||soluble ICAM1:1||stage smallcell lung cancer:1||standardized uptake value:1||stratified randomization trial:1||structural biology:1||surveillance:1||survival outcome:1||survival rate:1||systemic inflammatory markers:1||systemic therapy:1||targeted nextgeneration sequencing:1||telomere:1||tertiary lymphoid structure:1||testing:1||texture analysis:1||thirdgeneration TKI:1||threeweek schedule:1||threoninetomethionine mutation at codon 790 (T790M):1||thrombosis:1||thymic cancer:1||thymic carcinoma:1||thymic epithelial tumour (TET):1||thymoma:1||thyroid:1||thyroid cancer:1||time to progression:1||tissue:1||top 20 papers:1||topological transformation:1||total lesion glycolysis:1||trametinib:1||transcriptomics:1||transient asymptomatic pulmonary opacities:1||trastuzumab deruxtecan:1||trastuzumabpkrb:1||treatment outcome:1||tuberculosis:1||tumor:1||tumor mutation burden:1||tumor samples:1||tumorinfiltrating lymphocyte:1||tyrosine kinase inhibitor (TKI):1||tyrosinekinase inhibitor:1||ultrasonography:1||uncommon EGFR:1||uncommon mutations:1||urothelial carcinoma:1||vascular endothelial growth factor receptor (VEGFR):1||vascular endothelial growth factor receptor 1:1||viruses:1||vistusertib:1||wild type:1||18 FFDG PET/CT:1||18FFDG:1||18FFDG PET/CT:1||18Ffluorodeoxyglucose:1||1st line:1||20th anniversary:1||3rd generation:1||3rd generation EGFR TKI:1||ALK Inhibitor:1||ALK TKInaive:1||ALK gene rearrangements:1||ALK inhibitor:1||ALK positive NSCLC:1||ALK rearrangemen:1||ALK tyrosine kinase receptor:1||ALKpositive:1||ALKrearranged NSCLC:1||ASCL1:1||ATIC:1||AZD2811NP:1||AZD3759:1||AZD9291 First Time in Patients Ascending Dose Study (AURA):1||Abscopal effect:1||Acute kidney injury:1||Adagrasib:1||Adaptive Immunity:1||Adenocarcinoma in situ:1||Adjuvant concurrent chemoradiotherapy:1||Adjuvant radiotherapy:1||Adjuvant therapy:1||Advanced:1||Ampliseq:1||Anaplastic lymphoma kinase (ALK):1||Angiogenesis:1||Angiogenesis inhibitor:1||AntiPD1:1||Antiangiogenic agent:1||Antiangiogenic therapy:1||Antibodydrug:1||Antibodydrug conjugate:1||Anticancer:1||Apoptosis:1||Aprepitant:1||Asia:1||AsiaPacific:1||Asian population:1||Asian subpopulation:1||Asians:1||Asymptomatic brain metastases in NSCLC:1||Atezolizumab:1||Axitinib:1||BIM:1||BIM Deletion Polymorphism:1||BIM deletion polymorphism:1||BRAF:1||BRAF V600E:1||BRAF(V600) mutation:1||Base of tongue cancer:1||Bevacizumab:1||Bifunctional:1||Big data:1||Biomarker analysis:1||Biopsy:1||Bispecific antibody:1||Brain:1||Brain radiotherapy:1||Bronchioloalveolar carcinoma:1||Bulky nodal involvement:1||C797S mutation:1||CBSJukebox:1||CD117 antigen:1||CD28:1||CD8(+) T cells:1||COPD:1||COVID19:1||CT:1||CT lung neoplasms:1||CTLA4:1||CTLA4 antigen:1||CXCL13:1||California Cancer Registry:1||Cancer detection:1||Cancer prevention:1||Capecitabine:1||Carcinoembryonic antigen:1||Carcinoid tumor:1||Carcinoma, Esophageal neoplasm:1||Carcinoma, Nonsmallcell lung:1||Carcinoma, nonsmallcell lung:1||Carcinoma, squamous cell:1||Cardiac toxicity:1||Cardiotoxicity:1||Celiac lymph node:1||Cellfree DNA:1||Cellfree DNA (cfDNA):1||Central Nervous System:1||Cetuximab:1||Characteristic:1||Chemotherapyinduced nausea and vomiting:1||Chronic obstructive pulmonary disease (COPD):1||Cigarette smoking:1||Circulating tumor DNA (ctDNA):1||Classificatio:1||Clinical practice:1||Clinical practice patterns:1||Colorectal cancer (CRC):1||Combination:1||Combination strategy:1||Combination therapy:1||Companion diagnostics:1||Compassionate use pragram:1||Concurrent chemoradiation therapy:1||Concurrent chemoradiotherapy:1||Concurrent chemoradiation therapy:1||Consensus:1||Consensus statement:1||Consolidation:1||Copy number:1||Corneal epithelial change:1||Coronavirus disease 2019 outbreak (COVID19 outbreak):1||Cyclin D1:1||Cytarabine:1||DGGE:1||DLL3:1||DNA:1||DNA damage response:1||Dabrafenib:1||DeLLphi301:1||Definitive CCRT:1||Derivatives:1||Diseasefree survival:1||Dlco:1||Dovitinib:1||Driver oncogene:1||Drug development:1||Drug resistance:1||Drugassociated interstitial lung disease:1||Durable clinical benefit:1||EGER messenger RNA (mRNA):1||EGFR T790M:1||EGFR T790M mutations:1||EGFR T790Mpositive nonsmall cell lung cancer (NSCLC):1||EGFR antibodies:1||EGFR gene:1||EGFR inhibitor:1||EGFR monoclonal antibody:1||EGFR mutant NSCLC:1||EGFR tyrosine kinase inhibitor:1||EGFRMutant:1||EGFRTKIs:1||EGFRmutation:1||EGFR/MET ratio:1||EGFRm NSCLC:1||EGFT TKI:1||EORTC QLQC30:1||EORTC QLQLC13:1||ERK inhibitor:1||East Asian:1||Eastern Asia:1||Egfr:1||Epidemiology:1||Epidermal growth:1||Epidermal growth factor receptor inhibitor:1||Epidermal growth factor receptor mutation:1||Epidermal growth factor receptor tyrosine kinase inhibitors:1||Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs):1||ErbB3:1||Excision repair crosscomplementation group 1:1||Exon:1||Exon 20 insertion:1||Extracellular vesicle:1||F18FDG PET:1||F18fluorodeoxyglucose:1||F18fluorodeoxyglucose (FDG):1||FDG PET:1||FDG PET/CT:1||FGFR:1||FGFR inhibitor:1||FISH:1||FLAIR:1||FOLFOX:1||Far East:1||First line:1||Firstline:1||Firstline treatment:1||Fluorescence in situ hybridization:1||Followup:1||Fracture:1||Functioning:1||GGH:1||Gamma Knife:1||Gamma knife radiosurgery:1||Genetic alterations:1||Genetic heterogeneity:1||Genome:1||Global longitudinal strain:1||Groundglass nodule:1||Groundglass opacity:1||Guideline, Nonsmall cell lung cancer:1||HER2 amplification:1||HER2 mutation:1||HER3:1||HM61713:1||HNSCC:1||Head and neck squamous carcinoma:1||Health status:1||Hematology/Oncology:1||Heparin:1||Hepatocyte growth factor:1||Histologic transformation:1||Histology:1||Human papillomavirus:1||Hypercoagulability:1||Hyperuricemia:1||Hypopharyngeal neoplasms:1||IGF1R:1||IGFBP3:1||IL10:1||IL15:1||ITMIG:1||Idarubicin:1||Ifinatamab deruxtecan:1||IgG antibody:1||Imaging genomics:1||Immune check point:1||Immune therapy:1||Immunecheckpoint inhibitors:1||Immunerelated response:1||Immunosuppression:1||Impact:1||In situ hybridization:1||Incidence:1||Induction chemotherapy:1||Insulinlike growth factor1 inhibitor:1||Intensive care unit:1||Interstitial lung disease:1||Intracranial efficacy:1||Investigatorinitiated clinical trial:1||Irinotecan:1||JAK1 pathway:1||KML001:1||Key words:1||Korean:1||Korean ethnicity:1||L1:1||L858R:1||LASSO score:1||LUNG CANCER:1||Large cell neuroendocrine carcinoma:1||Lepidic:1||Leptomeningeal:1||Leptomeningeal carcino:1||Leptomeningeal carcinomatosis:1||Leptomeningeal seeding:1||Leukemia:1||Limitedstage:1||Local therapy:1||Locally advanced:1||Locally advanced nonsmall cell lung cancer:1||Locallyadvanced or metastatic ALK plus NSCLC:1||Locoregional recurrence:1||Lung Cancer:1||Lymph node metastasis:1||M:1||MDSC:1||MET Exon 14 Skipping:1||MET amplification in EGFR TKI resistance:1||MET exon 14 mutation:1||MET exon 14 skipping:1||MET inhibitor:1||MET inhibitors:1||METamplification:1||METex14 skipping NSCLC:1||MK1308:1||MK7684:1||Maintenance:1||Maintenance chemotherapy:1||Malignant mesothelioma:1||Masaoka&apos:1||Maximum tolerated dose:1||Mechani:1||Medical big data:1||Mesenchymalepithelial transtion tyrosine kinase receptor:1||Mesothelioma:1||Metabolic tumor volume:1||Metabolic tumour volume:1||Metachronous:1||Metastatic:1||MicroRNA:1||Microbiome:1||Moderately emetogenic chemotherapy:1||Molecular diagnostics:1||Molecular markers:1||Molecular profiling:1||Molecular sequencing:1||Molecular targeted therapy:1||Morbidity:1||Mortali:1||Mouse:1||Mucin:1||Mucinous adenocarcinoma:1||Mutant EGFR:1||Myeloid Derived Suppressor Cell:1||N:1||N1 adenocarcinoma:1||N1 disease:1||NEUROD1:1||NGS:1||NPC:1||NUT carcinoma:1||Necitumumab:1||Negative predictive value:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE